novo nordisk q3 news - Search News

Q3 Earnings Snapshot

The Motley Fool on MSN · 9h

Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today,

Novo Nordisk: Q3 Earnings Snapshot

The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 91 cents per share.

The Washington Post · 1d

Beasley: Q3 Earnings Snapshot

Beasley: Q3 Earnings Snapshot

Novo Nordisk Shares Climb

Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.

GlobalData on MSN · 9h

Strong Wegovy revenue growth for Novo Nordisk but shares dip

Novo Nordisk’s net profit of $3.94bn represents a 21% increase from Q3 2023. Net sales in the quarter jumped by the same amount, totalling $10.6bn. The company narrowed its sales growth for the full year 2024, down to 23% to 27% from 22% to 28% at constant exchange rates.

BioSpace · 10h

Novo Misses Overall Q3 Revenue Despite Beating Wegovy Sales Forecast, Narrows 2024 Outlook

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year guidance for revenue and operating profit.

1d

Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?

Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.

8h

NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View

Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 ...

Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More

In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated ...

13h

Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand

Novo Nordisk's Q3 2024 report highlights a 21% YoY sales increase with strong gains in GLP-1 diabetes and obesity drugs but ...

After Lilly's GLP-1 sales fumble, Novo reports mixed results on Ozempic, Wegovy

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results